Sevoflurane in COVID-19 ARDS (SevCov)

• Status: Completed
• Trial end date: 2021-07-16
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this trial is to study the effect of initial temporary sevoflurane sedation on mortality and persistent organ dysfunction (POD) in survivors at day 28 after ICU admission in the population of patients suffering from COVID-19 ARDS.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Zurich
• Collaborators: Cantonal Hospital of St. Gallen; Kantonsspital Münsterlingen; Triemli Hospital
• Treatments: Sevoflurane

Criteria

Inclusion Criteria:

• SARS-CoV-2 infection (positive testing) or computed tomography (CT) scan-suspected COVID-19 ARDS

• Male and female patients, age 18 to 85 years

• ICU patients with ARDS defined as PaO2/FiO2 < 200mmHg (=26.6kPa)

• Time of intubation not longer than 24 hours

• QTc Time (ECG) not longer than 470 ms ♂ (male)/ 480 ms ♀ (female)

• Sedation and mechanical ventilation in ICU

• Informed consent, signed by a representative or by an independent physician

Exclusion Criteria:

• High dose systemic corticosteroids in the phase before hospitalization (> 10mg/d prednisone or equivalent dose)

• Significant concomitant disease (acute cerebral vascular event, acute coronary syndrome, seizure, burn, neuromuscular disease)

• Organ transplant

• AIDS

• Pregnancy and/or breastfeeding

• Use of cytokine absorber